Molecular assessment of minimal residual disease in PBSC harvests provides prognostic information in neuroblastoma

被引：12
作者：
Chambon, F. [1 ,2 ,3 ]
Tchirkov, A. [3 ,4 ,5 ,6 ]
Pereira, B. [7 ]
Rochette, E. [1 ,2 ]
Demeocq, F. [1 ,2 ,3 ]
Kanold, J. [1 ,2 ,3 ]
机构：
[1] CHU Clermont Ferrand, Ctr Reg Cancerol & Therapie Cellulaire Pediat, Hop Estaing, Clermont Ferrand, France
[2] INSERM CIC 501, Clermont Ferrand, France
[3] Univ Clermont1, Fac Med, Clermont Univ, Clermont Ferrand, France
[4] CHU, EA ERTICa 4677, F-63003 Clermont Ferrand, France
[5] Ctr Lutte Canc Jean Perrin, Clermont Ferrand, France
[6] CHU Clermont Ferrand, Serv Cytogenet Med, Hop Estaing, Clermont Ferrand, France
[7] CHU Clermont Ferrand, Unite Biostat Delegat Rech Clin & Innovat, Clermont Ferrand, France
来源：
PEDIATRIC BLOOD & CANCER | 2013年 / 60卷 / 09期
关键词：
minimal residual disease; neuroblastoma; peripheral blood stem cells; RQ-PCR for tyrosine hydroxylase mRNA; STEM-CELL TRANSPLANTATION; HIGH-RISK NEUROBLASTOMA; BONE-MARROW; CONTAMINATION; CHILDREN; GRAFTS;
D O I：
10.1002/pbc.24538
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
As almost all patients with high-risk neuroblastomas have autograft, we aimed to determine if minimal residual disease (MRD) quantified by RT-PCR for tyrosine hydroxylase in PBSC is prognostic in neuroblastomas. PBSC harvests from 38 children were analyzed. Seven had harvests positive for TH-mRNA. Patients with a positive MRD had a lower 2-year-overall-survival compared to those with negative MRD (P=0.04) regardless of whether or not PBSC were re-infused. Patients in CR/VGPR group with positive MRD have hazard ratio of death at 7.3 [1.3-40.5]. In conclusion, molecular MRD status in PBSC of good response group may be of interest as a survival prognostic factor in high-risk neuroblastomas. Pediatr Blood Cancer 2013;160:E109-E112. (c) 2013 Wiley Periodicals, Inc.
引用
收藏
页码：E109 / E112
页数：4
相关论文
共 50 条
  • [21] Mesenchymal Neuroblastoma Cells Are Undetected by Current mRNA Marker Panels: The Development of a Specific Neuroblastoma Mesenchymal Minimal Residual Disease Panel
    van Wezel, Esther M.
    van Zogchel, Lieke M. J.
    van Wijk, Jalenka
    Timmerman, Ilse
    Vo, Ngoc-Kim
    Zappeij-Kannegieter, Lily
    DeCarolis, Boris
    Simon, Thorsten
    van Noesel, Max M.
    Molenaar, Jan J.
    van Groningen, Tim
    Versteeg, Rogier
    Caron, Huib N.
    van der Schoot, C. Ellen
    Koster, Jan
    van Nes, Johan
    Tytgat, Godelieve A. M.
    [J]. JCO PRECISION ONCOLOGY, 2019, 3
  • [22] Highly sensitive assessment of neuroblastoma minimal residual disease in ovarian tissue using RT-qPCR-A strategy for improving the safety of fertility restoration
    Greze, Victoria
    Brugnon, Florence
    Chambon, Fanny
    Halle, Pascale
    Canis, Michel
    Amiot, Clotilde
    Gremeau, Anne-Sophie
    Pereira, Bruno
    Peralta, Yania Yanez
    Tchirkov, Andrei
    Kanold, Justyna
    [J]. PEDIATRIC BLOOD & CANCER, 2017, 64 (05)
  • [23] Minimal Residual Disease Assessment in Multiple Myeloma Patients: Minimal Disease With Maximal Implications
    Charalampous, Charalampos
    Kourelis, Taxiarchis
    [J]. FRONTIERS IN ONCOLOGY, 2022, 11
  • [24] The role of p14ARF methylation in neuroblastoma minimal residual disease
    Erbayraktar, Zubeyde
    Zadeoglulari, Zeynep
    Aktas, Safiye
    Ellidokuz, Hulya
    Kirkali, Guldal
    Olgun, Nur
    [J]. TURKISH JOURNAL OF BIOCHEMISTRY-TURK BIYOKIMYA DERGISI, 2012, 37 (02): : 129 - 138
  • [25] Usefulness of tyrosine hydroxylase mRNA for diagnosis and detection of minimal residual disease in neuroblastoma
    Ito, R
    Asami, S
    Kagawa, S
    Motohashi, S
    Shichino, H
    Chin, M
    Yoshida, Y
    Nemoto, N
    Mugishima, H
    Suzuki, T
    [J]. BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2004, 27 (03) : 315 - 318
  • [26] Molecular detection of minimal residual disease in multiple myeloma
    Bai, Yinlei
    Orfao, Alberto
    Sang Chim, Chor
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2018, 181 (01) : 11 - 26
  • [27] Stability of PCR Targets for Monitoring Minimal Residual Disease in Neuroblastoma
    Stutterheim, Janine
    Zappeij-Kannegieter, Lily
    Ora, Ingrid
    van Sluis, Peter G.
    Bras, Johannes
    den Ouden, Emmy
    Versteeg, Rogier
    Caron, Huib N.
    van der Schoot, C. Ellen
    Tytgat, Godelieve A. M.
    [J]. JOURNAL OF MOLECULAR DIAGNOSTICS, 2012, 14 (02) : 168 - 175
  • [28] Molecular Monitoring of Minimal Residual Disease in the Peripheral Blood of Patients with Multiple Myeloma
    Korthals, Mark
    Sehnke, Nina
    Kronenwett, Ralf
    Schroeder, Thomas
    Strapatsas, Tobias
    Kobbe, Guido
    Haas, Rainer
    Fenk, Roland
    [J]. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2013, 19 (07) : 1109 - 1115
  • [29] B Lymphoblastic Leukemia Minimal Residual Disease Assessment by Flow Cytometric Analysis
    Shaver, Aaron C.
    Seegmiller, Adam C.
    [J]. CLINICS IN LABORATORY MEDICINE, 2017, 37 (04) : 771 - +
  • [30] Fluorescence in situ hybridization evaluation of minimal residual disease on stem-cell harvests
    Díez-Martín, JL
    Buño, I
    Llamas, P
    Gosálvez, J
    López-Fernández, C
    Polo, N
    Regidor, C
    [J]. CANCER DETECTION AND PREVENTION, 2000, 24 (02): : 169 - 172
12345